AI may help spot dangerous prostate cancer and spare men from needless biopsies

NCT ID NCT07760857

First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time

Summary

This study tests a new AI framework called Cad-MMFF that combines clinical information, ultrasound, and MRI images to better detect clinically significant prostate cancer. The goal is to see if this approach can reduce unnecessary biopsies and safely limit the use of MRI. The study involves Chinese men aged 50 and older who are suspected of having prostate cancer and are scheduled for a biopsy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
An AI-based diagnostic framework (Cad-MMFF) that combines clinical, ultrasound, and MRI data
What this could lead to
If successful, this AI tool could help doctors better identify clinically significant prostate cancer, sparing many men from unnecessary biopsies and MRIs.
What could go wrong
This is an early-stage study, and the AI's accuracy may not hold up in broader populations. It also depends on image quality and complete data, which may not always be available.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER (DIAGNOSIS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • North District Hospital

    Sheung Shui, Hong Kong

  • Prince of Wales Hospital

    Hong Kong, Hong Kong

More trials for these conditions

Other studies related to the condition(s) this trial covers.